Skip to main content
OpenTrials
Completed

NCT Number: NCT05012423

FTIH Study of ECC0509 in Healthy Volunteers

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

CMAX Clinical Research

Adelaide, South Australia, 5000, Australia

About this study

This study will be conducted in up to seven cohorts of Single Ascending Dose (SAD) & 3 cohorts of Multiple Ascending Dose (MAD). SAD will consist of a staggered dosing approach with a dose range from 1mg to 80mg. Staggered dosing approach will not be deployed for MAD cohorts with a dose range of 8mg to 40mg. In the MAD cohort, the effect of food will also be assessed by comparing the PK profile of Day 10 fed conditions against Day 14 fasted conditions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Healthy male or non-childbearing potential female
  • Age ≥18 and ≤65 years old
  • BMI ≥18.0 and ≤32.0 kg/m2
  • Male participants agree to use contraception
  • No clinically significant abnormal findings in physical examination, 12-lead electrocardiogram (ECG), laboratory tests, or medical history
  • Able to understand and sign informed consent

Key Exclusion Criteria:

  • Significant allergic reactions to any drug.
  • History of significant drug abuse or alcohol abuse within 1 year prior to screening
  • Concomitant participation in any investigational study of any nature
  • Use of any concomitant medication except for the occasional use of acetaminophen (up to 2 g daily)
  • Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing.
  • Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol breath test, or medical history which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Treatment and study plan

Placebo

Drug

Matching Placebo will be administered as oral capsules.

ECC0509

Drug

ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.

Primary outcomes

  1. Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21.

    Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.

Secondary outcomes

  1. ECC0509 PK parameters: Cl/F

    Time frame: SAD: Up to Day 8.

    Apparent clearance

  2. ECC0509 PK parameters: Vz/F

    Time frame: SAD: Up to Day 8.

    Apparent volume of distribution

  3. ECC0509 PK parameter: AUC0-24

    Time frame: MAD: Up to Day 21

    Area under the concentration-time curve from time zero to time 24 hours

  4. ECC0509 PK parameter: Cmax ss

    Time frame: MAD: Up to Day 21

    Maximal observed concentration at steady-state

  5. ECC0509 PK parameter: Tmax ss

    Time frame: MAD: Up to Day 21

    Time when the maximal concentration is observed at steady-state

  6. ECC0509 PK parameter: Tlag ss

    Time frame: MAD: Up to Day 21

    Time prior to the first measurable (non-zero) concentration at steady-state

  7. ECC0509 PK parameters: Cmax

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

    Maximal observed concentration

  8. ECC0509 PK parameter: Tmax

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

    Time when the maximal concentration is observed

  9. ECC0509 PK parameter: AUC0-t

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

    Area under the curve up to the last quantifiable time-point

  10. ECC0509 PK parameter: Cmin ss

    Time frame: MAD: Up to Day 21

    Minimal observed concentration at steady-state

  11. ECC0509 PK parameter: T½ el

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

    Terminal elimination half-life

  12. ECC0509 PK parameter: Kel

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

    Terminal elimination rate constant

  13. ECC0509 PK parameter: Clss/F

    Time frame: MAD: Up to Day 21

    Apparent body clearance at steady-state

  14. ECC0509 PK parameter: Vz ss/F

    Time frame: MAD: Up to Day 21

    Apparent volume of distribution at steady-state

  15. ECC0509 PK parameter: AUC0-τ

    Time frame: MAD: Up to Day 21

    Area under the concentration-time curve for one dosing interval (τ) at steady state.

  16. ECC0509 PK parameters: AUC0-inf

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

    Area under the concentration-time curve from time zero to infinity

  17. ECC0509 PK parameters: Residual area

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

    Percentage of AUC0-inf due to extrapolation from the time of the last observed concentration to infinity

  18. PD Parameter: SSAO

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21.

    plasma semicarbazide-sensitive amine oxidase (SSAO) activity.

Sponsors and collaborators

Lead sponsor

Eccogene

Industry

Registry information

Official study title

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, First-Time-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ecc0509 in Healthy Volunteers

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Aug 19, 2021
Registry last updated
Sep 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.